BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37726740)

  • 1. Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK /mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death.
    El-Sewedy T; Salama AF; Mohamed AE; Elbaioumy NM; El-Far AH; Albalawi AN; Elmetwalli A
    BMC Complement Med Ther; 2023 Sep; 23(1):329. PubMed ID: 37726740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment.
    Elmetwalli A; Abdel-Monem MO; El-Far AH; Ghaith GS; Albalawi NAN; Hassan J; Ismail NF; El-Sewedy T; Alnamshan MM; ALaqeel NK; Al-Dhuayan IS; Hassan MG
    Med Oncol; 2024 Apr; 41(5):106. PubMed ID: 38575697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis.
    Al-Noshokaty TM; Mesbah NM; Abo-Elmatty DM; Abulsoud AI; Abdel-Hamed AR
    Life Sci; 2022 Aug; 303():120675. PubMed ID: 35640776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
    Saraswati S; Alhaider A; Abdelgadir AM; Tanwer P; Korashy HM
    Cell Commun Signal; 2019 Oct; 17(1):127. PubMed ID: 31619257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The natural medicinal fungus Huaier promotes the anti-hepatoma efficacy of sorafenib through the mammalian target of rapamycin-mediated autophagic cell death.
    Zhang Z; Shen C; Zhou F
    Med Oncol; 2022 Sep; 39(12):221. PubMed ID: 36175804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways.
    Üremiş MM; Üremiş N; Türköz Y
    Steroids; 2023 Oct; 198():109261. PubMed ID: 37355001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid.
    Yurdacan B; Egeli U; Guney Eskiler G; Eryilmaz IE; Cecener G; Tunca B
    J Pharm Pharmacol; 2019 Jul; 71(7):1119-1132. PubMed ID: 31025377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
    Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer Effect of Amygdalin (Vitamin B-17) on Hepatocellular Carcinoma Cell Line (HepG2) in the Presence and Absence of Zinc.
    El-Desouky MA; Fahmi AA; Abdelkader IY; Nasraldin KM
    Anticancer Agents Med Chem; 2020; 20(4):486-494. PubMed ID: 31958042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
    Lai YL; Wang KH; Hsieh HP; Yen WC
    J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma.
    Jing W; Shuo L; Yingru X; Min M; Runpeng Z; Jun X; Dong H
    Biochem Biophys Res Commun; 2019 Oct; 519(1):41-45. PubMed ID: 31481232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting AMPK, mTOR and β-Catenin by Combined Metformin and Aspirin Therapy in HCC: An Appraisal in Egyptian HCC Patients.
    Abdelmonsif DA; Sultan AS; El-Hadidy WF; Abdallah DM
    Mol Diagn Ther; 2018 Feb; 22(1):115-127. PubMed ID: 29094287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of Anti-Proliferative and Apoptotic Effects of Sorafenib Using miR-27a Inhibitor in Hepatocellular Carcinoma Cell Lines.
    Abdel Wahab AHA; Ayad EG; Abdulla MS; Sharada HM; Ashmawy AM
    Asian Pac J Cancer Prev; 2021 Sep; 22(9):2951-2958. PubMed ID: 34582667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
    Bort A; Sánchez BG; Mateos-Gómez PA; Vara-Ciruelos D; Rodríguez-Henche N; Díaz-Laviada I
    Mol Oncol; 2019 May; 13(5):1311-1331. PubMed ID: 30959553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance.
    Chen S; Du Y; Xu B; Li Q; Yang L; Jiang Z; Zeng Z; Chen L
    Oncogene; 2021 May; 40(19):3378-3393. PubMed ID: 33875785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression.
    Wu MH; Chiu YF; Wu WJ; Wu PL; Lin CY; Lin CL; Hsieh YH; Liu CJ
    Environ Toxicol; 2018 Dec; 33(12):1237-1244. PubMed ID: 30187994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
    Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
    Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amygdalin potentiates the anti-cancer effect of Sorafenib on Ehrlich ascites carcinoma and ameliorates the associated liver damage.
    Attia AA; Salama AF; Eldiasty JG; Mosallam SAE; El-Naggar SA; El-Magd MA; Nasser HM; Elmetwalli A
    Sci Rep; 2022 Apr; 12(1):6494. PubMed ID: 35444229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
    Dai N; Ye R; He Q; Guo P; Chen H; Zhang Q
    Oncol Rep; 2018 Dec; 40(6):3235-3248. PubMed ID: 30272354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isoquercitrin induces apoptosis and autophagy in hepatocellular carcinoma cells via AMPK/mTOR/p70S6K signaling pathway.
    Shui L; Wang W; Xie M; Ye B; Li X; Liu Y; Zheng M
    Aging (Albany NY); 2020 Nov; 12(23):24318-24332. PubMed ID: 33260158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.